• To develop the product range: development of new forms, research into new indications, winning new international markets. E.g.: colitis caused by Clostridium difficile, Crohn's disease, inflammatory bowel disease, etc.
• To develop innovative substances, particularly for the central nervous system, and specific competence in epileptology: in 2007 DIACOMIT® has been granted the agreement for the 27 countries of the EU.
• To scientifically improve particular products which have been acquired, such as STRESAM®, which has become one of the main non-benzodiazepine anxiolytics available in France, or the injectable analgesic ACUPAN®, which was purchased in 1997 and which is developing positively in the treatment of postoperative pain.
• To innovate with new pharmaceutical forms.

Last Updated : January 6, 2009

© 2009 Biocodex - All Rights Reserved

Terms of Use